Fate Therapeutics
FATE
265 hedge funds and large institutions have $5.67B invested in Fate Therapeutics in 2021 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 103 increasing their positions, 84 reducing their positions, and 42 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 84
0.09% more ownership
Funds ownership: 100.46% → 100.55% (+0.09%)
3% less funds holding
Funds holding: 272 → 265 (-7)
12% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 42
15% less funds holding in top 10
Funds holding in top 10: 13 → 11 (-2)
31% less capital invested
Capital invested by funds: $8.2B → $5.67B (-$2.53B)
65% less call options, than puts
Call options by funds: $8.95M | Put options by funds: $25.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$268M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$66.4M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$49M |
| 4 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
+$35.3M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$31.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$330M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$59.9M |
| 3 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
-$49.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$39.8M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$31.6M |
FATE Hedge Fund Activity: Q3 2021 in Review
265 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q3 2021, worth a combined $5.67B — down 31% from $8.2B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of FATE and 37 opened new positions — a net loss of 5 holders — while 84 trimmed existing stakes and 103 added.
The largest buyer was ARK Investment Management, adding an estimated $268M. The largest seller was Fidelity Investments, cutting an estimated $330M.
- 265 institutional investors held Fate Therapeutics (FATE) as of Q3 2021, down from 272 in Q2 2021.
- Funds reported $5.67B of Fate Therapeutics stock for Q3 2021, down 31% quarter-over-quarter.
- 37 funds opened new Fate Therapeutics positions in Q3 2021 and 42 closed out, a net change of -5 holders.
- The largest Fate Therapeutics buyer in Q3 2021 was ARK Investment Management, an estimated $268M added.
- The largest Fate Therapeutics seller in Q3 2021 was Fidelity Investments, an estimated $330M sold.
Based on aggregated 13F filings for Q3 2021.